We recently discovered a common mode of gene regulation in budding yeast, by which mRNA production represses protein expression. Whether this regulatory mechanism is conserved was unknown. Here we find that a similar mechanism regulates the human oncogene MDM2, which is transcribed from two promoters. Transcription from the distal MDM2 promoter produces a poorly translated mRNA isoform and transcription from the proximal promoter produces a well-translated transcript. Remarkably, we find that downregulation of transcription from the distal promoter markedly up-regulates expression from the proximal promoter and results in the loss of histone H3K36 trimethylation marks. Moreover, we observe transcript toggling between the two different MDM2 isoforms as a natural part of two distinct human embryonic stem cell differentiation programs. We conclude that the integrated gene repression mechanism recently identified in yeast is conserved in human cells.
INTRODUCTION
Recently, we defined a form of gene regulation that challenges the broad assumption that mRNA production leads to increased protein production (CHEN et al. 2017; CHIA et al. 2017) . We found that in budding yeast meiosis, the amount of protein for the conserved kinetochore protein Ndc80 is determined by an unexpected mechanism in which mRNA production from a more distal NDC80 promoter inhibits Ndc80 translation through integration of transcriptional and translational interference: the distal promoterdriven transcript cannot be efficiently translated into protein and its transcription interferes with the proximal NDC80 promoter activity in cis. In this manner, a 5'extended and poorly translated mRNA isoform represses the production of a canonical mRNA isoform and therefore inhibits Ndc80 protein production (CHEN et al. 2017; CHIA et al. 2017 ).
We showed that this integrated mode of regulation relies on three key features ( Figure   1A ) (CHEN et al. 2017; CHIA et al. 2017 ). First, a developmentally regulated switch between alternative promoters for the same gene leads to the usage of different transcription start sites (TSSs). Second, due to upstream open reading frame (uORF)mediated translational repression, the distal promoter-generated transcript is inefficiently translated. Third, transcription from the distal promoter represses the expression of the canonical mRNA isoform through co-transcriptional histone modifications. When all three factors act together, and only then, the activation of NDC80 transcription can result in a decrease in translation from this locus. We termed the distal promoter-generated transcript "NDC80 LUTI " for long undecoded transcript isoform, because, despite containing the entire NDC80 ORF, NDC80 LUTI is not efficiently translated into protein (CHEN et al. 2017; CHIA et al. 2017) .
We further found that this mechanism is common in budding yeast cells, with 379 other genes showing protein levels that are regulated in this manner over time through meiotic differentiation (CHENG et al. 2018) . While these studies were exclusively performed using budding yeast, two of the three hallmarks of LUTI-based gene repression are common in mammals, suggesting possible conservation of this integrated mechanism. First, almost half of human genes show evidence of alternative promoter usage, resulting in transcript isoforms that differ in their 5' leader (WANG et al. 2016 ). Second, transcripts with extended 5' leaders that contain uORFs result, in some cases, in a poorly translated transcript compared to isoforms with shorter 5' leaders (LAW et al. 2005 ; FLOOR AND DOUDNA 2016). These features are observed in global studies, and they were also independently defined for several genes, including TGFβ3, AXIN2, and Mouse double-minute 2 homolog (MDM2), an oncogene and repressor of the tumor suppressor p53 (ARRICK et al. 1994; BARAK et al. 1994; BROWN et al. 1999;  HUGHES AND BRADY 2005). For example, the MDM2 isoform produced from the distal P1 promoter contains a longer 5' leader than the one produced from the proximal P2 promoter ( Figure 1B ). This P1-derived MDM2 isoform is poorly translated due to the presence of two uORFs in its extended 5' leader (BROWN et al. 1999 
2011)
, but these cases have not involved production of ORF-encoding mRNAs, and most importantly, the link between this type of transcriptional control and differentially translated transcripts has not been explored. Our interpretation of previous studies suggested that the same type of mechanism that we discovered in yeast might control the human MDM2 locus. Here, we report evidence that this is indeed the case and that this integrated mode of LUTI-based regulation is conserved from yeast to human.
RESULTS AND DISCUSSION
A key prediction, if MDM2 were regulated by a LUTI-based mechanism, would be an inverse relationship between the presence of the two MDM2 transcript isoforms, such that reduction in transcription from P1 should lead to increased transcription from P2. To directly test this prediction, we inhibited transcription from P1 by using CRISPRi (GILBERT et al. 2013) . To this end, we first examined MCF-7 breast cancer cells stably encoding the catalytically dead dCas9. Expressing each of four different single guide RNAs (sgRNAs) targeting the P1 promoter region led to a modest but significant increase, of up to 2-fold, in the P2-derived MDM2 PROX transcript levels, which was associated with the reduction of transcription from P1 (Figure 2A and Figure S1 ). This result was notable, given that the maximal knockdown of P1 activity was only 40% relative to control cells in these lines ( Figure 2A ). We tried to enhance the P1 transcriptional knockdown by using CRISPRi in MCF-7 cells that carry a version of dCas9 fused to the Krüppel-associated box (KRAB) transcriptional repression domain (GILBERT et al. 2013 ). However, targeting of dCas9-KRAB to the P1 promoter led to repression of both the P1 and P2 promoters ( Figure S2 ). This finding is consistent with the long-range effect of the KRAB domain up to 1Kb (GILBERT et al. 2014), beyond the 845 bp distance between the P1 and P2 regulated transcription start sites. Therefore, we performed all subsequent experiments using cell lines that stably expressed dCas9 without the KRAB domain, as this first-generation version of CRISPRi allowed us to achieve promoter-specific repression.
We further probed the relationship between P1 and P2 by knockdown of the gene encoding p53 (TP53) in MCF-7 cells using CRISPRi. Given that p53 is a wellcharacterized transcriptional activator for P2, it was not surprising that TP53 knockdown resulted in a significant, 43% reduction of the P2-derived MDM2 PROX transcript ( Figure   2B , left panel). However, additional CRISPRi knockdown of the P1-derived transcript, hereon referred to as MDM2 LUTI , still resulted in the transcriptional activation of P2, as evidenced by the 2-to 3-fold increase in MDM2 PROX levels in this background compared to the TP53 knockdown alone ( Figure 2B , right panel; Figure S3 ). The observation that MDM2 LUTI repression leads to an increase in MDM2 PROX expression, even in cells with reduced p53 levels, suggests that transcription from P1 actively represses P2 activity and that relief of this repression alone can lead to increased expression of MDM2 PROX independent of p53.
To test whether MDM2 LUTI based repression occurs in a different cell type, we performed similar experiments in K562, a TP53 -/myeloid leukemia cell line that routinely shows robust CRISPRi-based repression (GILBERT et al. 2014 ). Inhibition of MDM2 LUTI transcription in these cells resulted in a dramatic increase (up to 10-fold) in MDM2 PROX expression ( Figure 3A ). We achieved a range of MDM2 LUTI knockdown efficiencies in this cell line and, importantly, found that the degree of P1 downregulation generally correlated with the degree of P2 activation ( Figure 3A 
2017). However its involvement in promoter repression has been less clear.
Interestingly, in zebrafish, H3K36me3 mark is present in the promoter regions of quiescent genes that are developmentally regulated during spermatogenesis (WU et al.
2011).
We found that down-regulation of MDM2 LUTI expression resulted in more than 3-fold decrease in the H3K36me3 signal over the P2 promoter ( Figure 3B , Figure S4 ). In contrast, H3K36me3 signal remained high within the MDM2 gene body, likely due to increased MDM2 PROX transcription under these conditions. These data are consistent with a mechanism whereby MDM2 LUTI expression represses transcription from the P2 promoter through co-transcriptional histone modifications, and provide further support for a model in which the proximal MDM2 promoter is controlled by the same mechanism defined in yeast. Based on these findings, we propose that the LUTI-based gene regulation is conserved from yeast to human.
In budding yeast, developmentally controlled switching between the LUTI and canonical mRNA isoforms occurs pervasively during meiotic differentiation (CHENG et al. 2018).
We tested whether such transcript toggling naturally occurs in human cells by using two different human Embryonic Stem Cell (hESC) differentiation models. In human hESCs, both MDM2 transcript isoforms were expressed ( Figure 4A ). When these cells were induced to undergo neuronal differentiation, a switch in transcript isoform expression from MDM2 PROX to MDM2 LUTI was evident ( Figure 4B ). This inverse correlation between MDM2 PROX and MDM2 LUTI transcript levels was most pronounced between hESCs and neuronal precursors (NPCs) ( Figure 4B ). We also observed an anti-correlation between MDM2 PROX and MDM2 LUTI expression as hESCs differentiated into an endodermal fate, as determined by endoderm-specific markers ( Figure 4C , Figure S5 ). This inverse pattern of proximal and distal promoter usage seen during hESC differentiation suggests that the LUTI-based mechanism regulates MDM2 expression during normal cellular differentiation. here suggests that the broad use of this mechanism for developmental modulation of gene expression may be conserved.
In summary, we report here that the LUTI-based mechanism, initially defined for NDC80 argue that its two promoters are fundamentally different in function. The P1 promoter produces a poorly translated MDM2 LUTI transcript and the production of MDM2 LUTI from this promoter interferes with P2 activity in cis, reducing the transcription of the welltranslated MDM2 PROX isoform. Therefore, P1-driven MDM2 LUTI mRNA production serves to downregulate MDM2 expression ( Figure 5 ). 
MATERIALS AND METHODS

Cell lines
MCF-7-dCas9 and -dCas9-KRAB cells were cultivated at 37°C with 5% CO 2 in high glucose Dulbecco's modified Eagle media (GlutaMax, Gibco) supplemented with 10% FBS and 1% penicillin-streptomycin. K562-dCas9 cell lines were cultivated at 37°C with 5% CO 2 in RPMI1640 media (Gibco) supplemented with 10% FBS and 10mM HEPES.
hESCs (WIBR3 NIH#0079) were maintained in culture as described in (LENGNER et al. 
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